Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.

ABSTRACT: BACKGROUND:While guidelines recommend anticoagulation for all atrial fibrillation (AF) patients ≥75 years, evidence for the net clinical benefit (NCB) of anticoagulant in older adults is sparse. We sought to determine the association between age and NCB of anticoagulation in older adults with AF. METHODS AND RESULTS:We examined adults ≥75 years with incident AF in the Anticoagulation and Risk Factors in Atrial Fibrillation-Cardiovascular Research Network cohort. Using a Markov state transition model, we estimated the lifetime NCB of warfarin and apixaban relative to no treatment in quality-adjusted life years (QALYs). In the decision model, each month patients face a chance of stroke, hemorrhage, or death from a competing cause; the likelihood of each is a function of individual patients'

SUBMITTER: Shah SJ 

PROVIDER: S-EPMC7117790 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature